DCE-2

DCE-2 (compound 5) is a PROTAC targeting CREB binding protein (CBP) and E1A-associated protein (EP300), which was developed based on the crystal structure of bromodomain (BRD) inhibitors. dCE-2 is composed of E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), PROTAC Linker tert-Butyl 11-aminoundecanoate (HY-130715) (black part) and PROTAC target protein ligand EP300/CBP ligand 2 (HY-161960) (red part), of which the target protein ligand activity control is EP300/CBP ligand 1 (HY-161959), and the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C10-Boc (HY-161961) [1].

Product Specifications

UNSPSC

12352005

Target

Histone Acetyltransferase; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dce-2.html

Smiles

O=C(N1C2CCC(NC2=O)=O)C3=CC=CC(NCCCCCCCCCCC(NC4=CC(C5=NN(C)C=C5)=CC(C(NC6=CC=CC7=C6C=C(C)N=N7)=O)=C4)=O)=C3C1=O

Molecular Formula

C44H47N9O6

Molecular Weight

797.90

References & Citations

[1]Cheng-Sánchez I, et al. Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity. JACS Au. 2024 Aug 8;4 (9) :3466-3474.